KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) Leases (2017 - 2026)

Pacific Biosciences Of California has reported Leases over the past 8 years, most recently at $41.7 million for Q4 2025.

  • For Q4 2025, Leases rose 159.12% year-over-year to $41.7 million; the TTM value through Dec 2025 reached $41.7 million, up 159.12%, while the annual FY2025 figure was $41.7 million, 159.12% up from the prior year.
  • Leases for Q4 2025 was $41.7 million at Pacific Biosciences Of California, down from $42.6 million in the prior quarter.
  • Over five years, Leases peaked at $46.6 million in Q4 2021 and troughed at $16.1 million in Q4 2024.
  • A 5-year average of $34.6 million and a median of $37.3 million in 2023 define the central range for Leases.
  • Biggest five-year swings in Leases: tumbled 50.63% in 2024 and later surged 159.12% in 2025.
  • Year by year, Leases stood at $46.6 million in 2021, then dropped by 14.7% to $39.8 million in 2022, then fell by 18.03% to $32.6 million in 2023, then tumbled by 50.63% to $16.1 million in 2024, then surged by 159.12% to $41.7 million in 2025.
  • Business Quant data shows Leases for PACB at $41.7 million in Q4 2025, $42.6 million in Q3 2025, and $43.5 million in Q2 2025.